Study unveils novel strategy for diabetes treatment

WASHINGTON: Combining a once-popular but largely abandoned treatment for Type 2 diabetes with another drug could be used again to eliminate problematic side effects, say the findings of a novel study. Rosiglitazone, sold under the brand name Avandia, won Food and Drug Administration approval in 1999 and became a leading treatment for Type 2 diabetes, capable of increasing insulin sensitivity and glucose tolerance. It fell out of favour after studies raised concerns about the risk of a heart attack in some patients, as well as a risk for osteoporosis and evidence of increased weight gain and fluid...